Entia Biosciences, Inc.
ERGO
$0.00
$0.00-50.00%
OTC PK
| 12/31/2016 | 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | |
|---|---|---|---|---|---|
| Net Income | -49.86% | 28.09% | -47.32% | 10.12% | 17.33% |
| Total Depreciation and Amortization | -25.53% | 0.00% | 0.00% | -32.86% | -6.67% |
| Total Amortization of Deferred Charges | 955.00% | 25.00% | 77.78% | -57.14% | -62.50% |
| Total Other Non-Cash Items | 169.82% | -12.14% | 40.99% | 135.18% | -171.62% |
| Change in Net Operating Assets | -158.60% | -30.88% | 79.74% | -51.11% | 200.50% |
| Cash from Operations | -497.83% | 28.05% | -3.13% | -67.00% | 64.37% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | 42.22% | -800.00% | 86.49% |
| Cash from Investing | -- | 100.00% | 42.22% | -800.00% | 90.74% |
| Total Debt Issued | 579.20% | -50.00% | 57.89% | 90.00% | -- |
| Total Debt Repaid | 9.45% | 18.59% | -1.30% | -110.96% | 17.05% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 465.91% | 62.39% | -- | -- | -- |
| Cash from Financing | 787.74% | -52.81% | 54.15% | 86.42% | 35.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 571.34% | -188.20% | 173.86% | -40.12% | 87.78% |